Cardax, Inc. (CDXI)

Market Cap	83.00 -100.0%
Revenue (ttm)	500.71K -27.3%
Net Income	-5.43M
EPS	-6.77
Shares Out	825.18K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	125
Average Volume	635
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.0001 - 0.0040
Beta	28.93
RSI	37.99
Earnings Date	n/a

About Cardax

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a targ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: David Watumull
• Employees: 12
• Stock Exchange: OTCMKTS
• Ticker Symbol: CDXI

Financial Performance

In 2020, Cardax's revenue was $538,946, a decrease of -24.19% compared to the previous year's $710,949. Losses were -$5.06 million, -0.74% less than in 2019.